

**Policy for discontinuation of BioProcess™ and Cell and Gene Therapy products**

Cytiva is committed to continuing supplies of each of its BioProcess and Cell and Gene Therapy products for as long as Cytiva is aware that such products are being used in an approved, registered process for the manufacture of human biopharmaceuticals and vaccines.

Outside of the above, where Cytiva decides to discontinue a product, the following notification periods shall apply:

- For any bulk chromatography resin product, (including ReadyToProcess™ chromatography resin) customers shall be notified at least 3 years in advance of discontinuation.
- For single-use disposable products (ReadyToProcess products, Wave™ cell bags, Xcellerex™ bags and connectors, and process scale filtration products) and for standard cell culture products, customers shall be notified at least 1 year in advance of discontinuation.
- For BioProcess chromatography instruments and columns, a Change Control Notification will be sent out when production of the instrument or column is discontinued. For spare parts on instruments and columns installed by Cytiva an End-of-Service notification will be sent to all customers 1 year before the Service support period ends.
- For cell and gene therapy products (e.g. Xuri™, Sefia™, Sepax™) customers shall be notified at least 1 year in advance of discontinuation.

Notwithstanding the above, Cytiva reserves the right to discontinue a product immediately if and when regulatory or other legal reasons prevent its manufacture or distribution.

This policy applies to products for which subscription to change control notification is available on the web page [www.cytiva.com/rsf](http://www.cytiva.com/rsf).



Emmanuel Ligner  
President & CEO

12 June 2020



Olivier Loeillot  
Vice President, &  
GM BioProcess

12 June 2020



Catarina Flyborg  
Vice President &  
General Manager  
Cell & Gene Therapy

12 June 2020